Unknown

Dataset Information

0

Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.

ABSTRACT: Graft-versus-host disease (GVHD) is a common complication of hematopoietic stem cell transplant, which is known to be mediated by cytotoxic T-cell effectors and dysregulated inflammatory cytokines. Similarly, the lung injury observed in severe COVID-19 cases appears to be related to a massive production of pro-inflammatory cytokines. The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe COVID-19; nevertheless, no clinical observation of safety or efficacy of treatment with ruxolitinib in this context has been published yet. We describe a first case of severe COVID-19 developed after hematopoietic stem cell transplantation in a patient with a concomitant chronic GVHD (cGVHD), in which a treatment with ruxolitinib was administered with good tolerance and positive outcome.

SUBMITTER: Saraceni F 

PROVIDER: S-EPMC7361240 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.

Saraceni Francesco F   Scortechini Ilaria I   Mancini Giorgia G   Mariani Marianna M   Federici Irene I   Gaetani Mariana M   Barbatelli Paolo P   Minnucci Maria Luisa ML   Bagnarelli Patrizia P   Olivieri Attilio A  

Transplant infectious disease : an official journal of the Transplantation Society 20200714 1

Graft-versus-host disease (GVHD) is a common complication of hematopoietic stem cell transplant, which is known to be mediated by cytotoxic T-cell effectors and dysregulated inflammatory cytokines. Similarly, the lung injury observed in severe COVID-19 cases appears to be related to a massive production of pro-inflammatory cytokines. The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe C  ...[more]

Similar Datasets

Unknown Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab.
| S-EPMC10608369 | biostudies-literature
Unknown First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review.
| S-EPMC7239570 | biostudies-literature
Unknown Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.
| S-EPMC7507116 | biostudies-literature
Unknown Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
| S-EPMC11888538 | biostudies-literature
Unknown The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.
| S-EPMC7422131 | biostudies-literature
Unknown Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis.
| S-EPMC11882550 | biostudies-literature
Unknown Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
| S-EPMC3625710 | biostudies-literature
Unknown Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients.
| S-EPMC8422561 | biostudies-literature
Unknown Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
| S-EPMC5608321 | biostudies-literature
Transcriptomics Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
2025-03-20 | GSE285821 | GEO